BioStack raises $9.5 million seed led by Peak XV for medical AI data

BioStack, a health-data start-up based in San Francisco and founded by Sanat Mishra and Parth Patwa, has raised $9.5 million in a seed funding round led by Peak XV Partners. The round, announced in the week of October 22, 2026, also drew Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator. BioStack builds datasets from hospital records that companies and researchers can use to train medical artificial intelligence (AI) systems, and it works with hospitals in the United States, India, Brazil and Argentina.

Medical AI tools, such as software that reads scans or flags patients at risk, are only as good as the data they learn from. Most hospital data is scattered across different systems and formats: a scan sits in one place, a doctor's notes in another, the prescriptions in a third. Bringing these together into clean, consistent datasets is slow and expensive, and that is the problem BioStack says it is solving. Investors are betting that companies building medical AI will pay for well-organised, legally sourced data.

The India link matters in two ways. First, Indian hospitals are among BioStack's data partners, which means Indian patient data, in de-identified form, may be used to train AI tools. De-identification means removing names and other details that could reveal who a patient is. Second, datasets that include patients from India, Brazil and Argentina, not only the US, could help developers test whether their tools work across different groups, if the data is handled properly.

That "if" is important. Health data is among the most sensitive personal information. In India, the Digital Personal Data Protection Act sets rules on consent and the handling of personal data, and patients and regulators will expect clear answers on how records are collected, de-identified and shared. The company has not published details of its consent and privacy processes in the coverage of the round, so those remain open questions.

For Indian founders and investors, the round is an example of an India-linked venture investor backing a young company that is global from the start. Peak XV vice-president Pushpak Kedia is quoted in the coverage of the round.

Short-term: BioStack will use the money to grow its hospital network and data platform, according to reports, and is likely to sign more hospital partners in its four markets.

Long-term: If it succeeds, BioStack could become a supplier of training data to medical AI developers. Its growth will also test how health-data rules in India and other countries handle cross-border use of patient records.

Who is affected: Hospitals that share data, patients whose de-identified records are used, medical AI developers, and regulators overseeing health data and privacy.

Questions and Answers